Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer : Institutional experience

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 5, 2014, Pages 1989-1992

  Gogia, Ajay ^a   Raina, Vinod ^a   Deo, Suryanarayan Vishnu ^a   Shukla, Nootan Kumar ^a   Mohanti, Bidhu Kalyan ^a   Sharma, Daya Nand ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Breast cnacer; Chemotherapy; Outcome; Response; Taxane and anthracycline

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DOCETAXEL; EPIRUBICIN; TAXANE; TAXOID;

ADJUVANT THERAPY; ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899111050     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.5.1989     Document Type: Article

References (26)

1. Baltali E, Altundag MK, Onat DA, et al (2002). Neoadjuvant chemotherapy with Taxotere-epirubicin-5-fluorouracil (TEF) in loco regionally advanced breast cancer: A preliminary report. Tumori, 88, 474-7.
2. Baselga J, Bradbury I, Eidtmann H, et al (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379, 633-8.
3. Bull JM, Tormey DC, Li SH (1978). A randomised comparative trial of adriamycine versus methotrexate in combinationdrug therapy. Cancer, 41, 1649-57.
4. Cortazar P, Zhang L, Untch M, et al (2012). Meta-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). Cancer Res, 18, 72-93.
5. Chopra R(2001).The Indian scene. J Clin Oncol, 19, 106-11.
6. Deo SV, Bhutani M, Shukla NK, et al (2003). Randomized trial comparing neoadjuvant vs adjuvant chemotherapy in locally advanced breast cancer (T4bN0-2M0). J Surg Oncol, 84, 192-7.
7. Early Breast Cancer Trialists Collaborative Group (1998). Polychemotherapy for early breast cancer: an overview of randomised trials. Lancet, 352, 930-42.
8. Gianni L, Eiermann W, Semiglazov V, et al (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375, 377-84.
9. Giordano SH (2003). Update on locally advanced breast cancer. The Oncologist, 8, 521-30.
10. Gradishar WJ, Wedam SB, Jahanzeb M, et al (2005). Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol, 16, 1297-304.
11. Guarneri V, Frassoldati A, Bottini A, et al (2012). Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol, 30, 1989-99.
12. Gupta D, Raina V, Rath GK, et al (2011). Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapyin locally advanced breast cancer and comparison with anthracycline-based chemotherapies: Eight-year experience from single centre. Indian J Cancer, 48, 410-14.
13. Manoharan N, Tyagi BB, Raina V (2010). Cancer incidences in rural Delhi-2004-05. Asian Pac J Cancer Prev, 11, 73-7.
14. Mathew J, Asgeirsson KS, Agrawal A, et al (2007). Neoadjuvant chemotherapy in locally advanced primary breast cancers: The Nottingham experience. EJSO, 33, 972-76.
15. Papademetriou K, Ardavanis A, Kountourakis P (2010). Neoadjuvant chemotherapy for locally advanced breast cancer:Focus on chemotherapy and biological targeted treatments' armamentarium. J Thoracic Disease, 2, 160-8.
16. Phua CE, Bustam AZ, Yusof MM, et al (2012). Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting. Asian Pac J Cancer Prev, 13, 4623-6.
17. Pierga JY, Delaloge S, Espie M, et al (2010). A multicenter randomized phase II study of sequential epirubicin/ cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat, 122, 429-37.
18. Raina V, Medhi K, Deo S (2007). Shukla NK, Mohanti BK, Rath GK. Outcome of combined modality treatment of 412 cases of locally advanced breast cancer (LABC): Data from a tertiary cancer center in India. Breast Cancer Res Treat, 106, 1-350
19. Rastogi P, Anderson SJ, Bear HD, et al (2008). Preoperative chemo-therapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 26, 778-85.
20. Sikov WM, Dizon DS, Strenger R, et al (2009). Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol, 27, 4693-99.
21. Sikov W, Berry DA, Perou CM, et al (2013). Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triplenegative breast cancer (TNBC): CALGB 40603 (Alliance). San Antonio Breast Cancer Symposium. Abstract, 5-14.
22. Untch M, Rezai M, Loibl S, et al (2010). Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol, 28, 2024-31.
23. Untch M, Loibl S, Bischoff J, et al (2012). Lapatinib versus trastuzumab in combination with neoadjuvant anthracyclinetaxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol, 13, 135-9.
24. von Minckwitz G, Eidtmann H, Rezai M, et al (2012). Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med, 366, 299-309.
25. Von Minckwitz G, Kummel S, Vogel P, et al (2008). Intensified neo-adjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst, 100, 552-62.
26. Yao X, Hosenpud J, Chitambar CR (2012). A phase ii study of concurrent docetaxel, epirubicin and cyclophosphamide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer. J Cancer, 3, 145-51.